Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Enovix Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Enovix Corporation trades at $4.98 (market cap $1.09B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.1× Enovix Corporation's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | ENVX | |
|---|---|---|
Market Cap | $4.49B | $1.09B |
Sector | Health | Technology |
52-Week High | $28.06 | $15.93 |
52-Week Low | $20.06 | $4.84 |
Enterprise Value | $3.69B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ENVX trades at $5.62, up 4.85% today, but technical indicators signal a bearish trend with support at $5 and resistance at $6. The company reported Q1 2026 revenue above guidance and an EPS beat, yet remains unprofitable with a net margin of -499.64%. Analyst consensus is bullish with a $12.75 price target, driven by growth in silicon-anode batteries for AI devices, smart eyewear, and defense markets.
The stock offers high-risk, high-reward potential given its speculative growth story versus persistent losses. Key catalysts include scaling commercial production and smartphone qualification, but execution risks and cash burn require careful monitoring. Investors should weigh analyst optimism against fundamental challenges in the competitive battery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
